PCM
LEGN icon

Pavaki Capital Management’s Legend Biotech LEGN Stock Holding History

Pavaki Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Hold
6,305
– – 0.06% 135
2026
Q1 		$114K Buy
6,305
+5
+0.1% +$95 0.05% 147
2025
Q4 		$137K Buy
+6,300
New +$180K 0.05% 120

Other funds holding LEGN

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pavaki Capital Management's LEGN Position: Q2 2026 in Review

Pavaki Capital Management held its Legend Biotech (LEGN) position steady in Q2 2026 at 6,305 shares worth $182K. The position accounts for 0.06% of the portfolio, ranked #135.

Pavaki Capital Management first reported a position in LEGN in Q4 2025 and has held it in 3 quarters since. 201 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Pavaki Capital Management held 6,305 shares of Legend Biotech worth $182K as of Q2 2026.
  • Pavaki Capital Management left its Legend Biotech share count unchanged in Q2 2026.
  • Legend Biotech made up 0.06% of Pavaki Capital Management's portfolio in Q2 2026, its #135 holding.
  • Pavaki Capital Management first reported a position in Legend Biotech in Q4 2025 and has held it in 3 quarters since.
  • 201 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.